Brief: Adma Biologics Receives FDA Approval For License Transfers For Bivigam And Nabi-Hb

ADMA Biologics

08/07/2019 13:36

July 8 (Reuters) - ADMA Biologics Inc  ADMA.O :
    * ADMA BIOLOGICS RECEIVES FDA APPROVAL FOR LICENSE TRANSFERS
FOR
BIVIGAM AND NABI-HB
    * ADMA BIOLOGICS - FDA NOTIFIED LICENSES FOR BIVIGAM &
NABI-HB
REVOKED FROM BIOTEST PHARMACEUTICALS & TRANSFERRED, ISSUED TO
CO'S U.S. LICENSE NO. 2019

Source text for Eikon:  ID:nGNX9fFJJB 
Further company coverage:  ADMA.O 

 (((Reuters.Briefs@thomsonreuters.com);;))